US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Insys Therapeutics

0.2911

0.0000

Volume:- -

Turnover:- -

Market Cap:22.10M

PE:-0.09

High:0.2911

Open:0.2911

Low:0.2911

Close:0.2911

52wk High:11.65

52wk Low:0.1420

Shares:75.92M

Float Shares:28.47M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.0707

EPS(LYR):-1.6809

ROE:--

ROA:--

PB:-0.51

PE(LYR):-0.17

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Insys Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.insysrx.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INSY/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INSY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INSY\",,,,,undefined,":{"symbol":"INSY","market":"US","secType":"STK","nameCN":"Insys Therapeutics","latestPrice":0.2911,"timestamp":1561492800000,"preClose":0.2911,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":28470288,"shares":75920000,"eps":-3.070704,"marketStatus":"Trading","change":0,"latestTime":"06-04 14:12:59 EDT","open":0.2911,"high":0.2911,"low":0.2911,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.070704,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780603200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1367467200000,"exchange":"NASDAQ","adjPreClose":0.2911,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INSY\",,,,,undefined,":{"symbol":"INSY","floatShares":28470288,"roa":"--","roe":"--","lyrEps":-1.680853,"shares":75920000,"dividePrice":0,"high":0.2911,"amplitude":0,"preClose":0.2911,"low":0.2911,"week52Low":0.142,"pbRate":"-0.51","week52High":11.65,"institutionHeld":0.2673,"latestPrice":0.2911,"eps":-3.070704,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.070704,"open":0.2911,"prevYearClose":0.2911},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INSY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-05-10","symbol":"INSY","fiscalQuarterEnding":"2019/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1557460800000,"reportTimeType":"","actualEps":-0.58},{"market":"US","date":"2019-03-07","symbol":"INSY","fiscalQuarterEnding":"2018/12","expectedEps":-0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"post","actualEps":-0.39},{"market":"US","date":"2018-11-05","symbol":"INSY","fiscalQuarterEnding":"2018/09","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1541394000000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2018-08-08","symbol":"INSY","fiscalQuarterEnding":"2018/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1533700800000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2018-05-08","symbol":"INSY","fiscalQuarterEnding":"2018/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INSY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INSY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.insysrx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":0.0505},{"period":"3month","weight":0.107},{"period":"6month","weight":0.1},{"period":"1year","weight":0.2653},{"period":"ytd","weight":0.1061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.","exchange":"NASDAQ","name":"Insys Therapeutics","nameEN":"Insys Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"INSY\",market:\"US\",,,undefined,":null}}